Open

NETs Treatment Study

In this study, researchers want to find out the highest safe dose of a drug called [212Pb]VMT-α-NET that can be used to treat neuroendocrine tumors.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

You will receive the study drug in a span of 4 treatment cycles. For the first cycle, you will have safety visits weekly and subsequent cycles are bi weekly. During each cycle you will receive study drug, blood draws, and 2 safety evaluations.

Incentives

Study Drug

In-person visits:
37

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

You have a neuroendocrine cancer that cannot be removed with surgery or has spread to other areas of the body
Other treatments have not worked to treat the neuroendocrine cancer besides radionuclide therapy

Not eligible if:

Your cancer has spread to your brain and requires treatment right now
You are pregnant or breastfeeding
You have another type of cancer that requires treatment right now, other than the neuroendocrine cancer

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

24-1339

ClinicalTrials.gov

NCT05636618

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.